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Background:  Clinical trials of vasodilators have produced disparate results in patients with heart failure and reduced or preserved ejection 
fraction (HFrEF; HFpEF). We compared the acute hemodynamic effects of arterial vasodilation with sodium nitroprusside (SNP) in HFpEF and HFrEF.
Methods:  Patients with HFrEF (n=175) and HFpEF (n=83) who underwent clinically-indicated invasive hemodynamic assessment at rest and during 
SNP were compared.
Results:  At baseline, patients with HFpEF displayed higher blood pressure (BP) and cardiac index (CI) compared with HFrEF, while pulmonary 
capillary wedge pressure (PCWP) and mean pulmonary artery pressure (PA) were similar (Table). Despite comparable reductions in systemic afterload 
(arterial elastance, Ea) and pulmonary vascular resistance index (PVRI), systemic BP dropped to greater extent in HFpEF. In contrast, patients with 
HFrEF displayed greater increases in stroke volume index (SVI) and cardiac index (CI) compared with HFpEF, with less drop in BP.
Conclusion: The hemodynamic response to arterial vasodilation is fundamentally different in HF patients with preserved versus reduced ejection 
fraction. Reduction in systemic blood pressure is exaggerated in HFpEF, while enhancement in stroke volume is greater in HFrEF. These findings may 
partially explain the treatment effect disparities noted in randomized trials for HFpEF and HFrEF. 
Baseline
Median (IQR) or ± SD
Change with SNP
Median (IQR) or ± SD
HFpEF HFrEF HFpEF HFrEF
SNP dose (mcg/kg/min) - - 1.5 (1,3) 2 (1,2)
Heart Rate (bpm) 70 (60, 76) 70 (62, 81) +4 ± 9 +2 ± 9
SBP (mmHg) 166 (144, 180) 113 (74, 92)* -51 (-28, -71) -22 (-11, -36)*
Ea (mmHg/ml) 2.0 (1.6, 2.8) 1.7 (1.5, 2.4)† -0.6 (-0.5, -1.2) -0.8 (-0.4, -1.3)
PCWP (mmHg) 25 (21,30) 25 (20,29) -9 (-12, -6) -7 (-13, -4)
Mean PA (mmHg) 41 (35, 48) 40 (33, 47) -11 (-7,-17) -10 (-6,-16)
CI (L/min/m2) 2.4 (2, 2.8) 2.0 (1.6, 2.3)* +0.3 ± 0.7 +0.9 ± 0.7*
SVI (ml/m2) 34 (28, 42) 27 (22, 34)* +4 ± 12 +11 ± 10*
PVRI (WU*m2) 6.5(4.3, 10.4) 7.0 (4.8, 9.5) -2.1 (-4.3, 0.4) -2.9 (-5, -1.4)
*p<0.001 compared with HFpEF; †p<0.05 compared with HFpEF
